Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Blueprint Medicines Corporation (NASDAQ: BPMC).

Full DD Report for BPMC

You must become a subscriber to view this report.


Recent News from (NASDAQ: BPMC)

Healthcare - Top 5 Gainers / Losers as of 12:20 AM (05/17/2018)
Gainers : LOXO +19% . RTTR +18% . SPPI +17% . EIGR +16% . BDSI +15% . More news on: Loxo Oncology, Ritter Pharmaceuticals, Spectrum Pharmaceuticals, Inc., Healthcare stocks news, , Stocks on the move, Read more ...
Source: SeekingAlpha
Date: May, 17 2018 12:21
Blueprint Medicines Announces Data Presentations at Upcoming ASCO and EHA Meetings Supporting Plans for Rapid Development of Avapritinib in Patients with Gastrointestinal Stromal Tumors and Systemic Mastocytosis
CAMBRIDGE, Mass. , May 17, 2018 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced two data presentations supporting plans for rapid deve...
Source: PR Newswire
Date: May, 17 2018 09:00
Loxo's RET candidate LOXO-292 shows treatment effect in early-stage study, but still lags Blueprint's BLU-667
Loxo Oncology (NASDAQ: LOXO ) is up  18%  premarket on light volume on the heels of its announcement of interim data from a Phase 1 clinical trial assessing RET inhibitor LOXO-292 in RET-mutated cancers. Tumor shrinkage was observed in almost 70% of patients. More news on: Loxo...
Source: SeekingAlpha
Date: May, 17 2018 07:57
Institutional Top Ideas Series: Opaleye Management
In the last entry of this series, we took a look at top ideas from Ra Capital Management, the best performing fund we´ve come across so far with heavily concentrated positions in their top ideas. Going forward, I hope to continue to delve into the portfolios of successful hedge funds ...
Source: SeekingAlpha
Date: May, 17 2018 01:52
Loxo Oncology +18% as cancer drug shows promise in early trial
Loxo Oncology (NASDAQ: LOXO ) +17.9% after-hours following preliminary results which showed that its new LOXO-292 experimental cancer drug led to tumor shrinkage in nearly 70% of patients regardless of where their cancer originated. More news on: Loxo Oncology, Blueprint Medicines, Hea...
Source: SeekingAlpha
Date: May, 16 2018 17:52
JF's Core Biotech Buys #15: Removal Of A Key Overhang, Buying Weakness In I-O, Updates And Adding To 2 Positions
Welcome to the fifteenth edition in the series "JF's Core Biotech Buys." Our model account utilizes a full position size of $5,000 and will hold up to 20 stocks. Trades will be less frequent with cost averages calculated at the day's close when an article is published. Depending on the size ...
Source: SeekingAlpha
Date: May, 14 2018 11:37
Pushing Preclinical: Wave Of Early-Stage Biotech IPOs Tests Investor Risk Appetite
Biotechs are among the most risky of IPOs due to the binary nature of the success… or failure of their drugs. In the past, most biotechs delayed public offerings until they at least showed clinical evidence of their safety or efficacy. But in 2018, biotechs are increasingly going publ...
Source: SeekingAlpha
Date: May, 09 2018 05:37
JF's Core Biotech Buys #14: Introducing Our Final 2 Positions & Taking Advantage Of Weakness In The I-O Space
Welcome to the fourteenth edition in the series "JF's Core Biotech Buys." Our model account utilizes a full position size of $5,000 and will hold up to 20 stocks. Trades will be less frequent with cost averages calculated at the day's close when an article is published. Depending on the size...
Source: SeekingAlpha
Date: May, 07 2018 15:40
Institutional Top Ideas Series: Orbimed Advisors
In the last entry of this series, we took a look at top ideas from Baker Bros. Advisors (whose performance has been struggling of late but they've built up a stellar reputation and track record of long term outperformance). Going forward, I hope to continue to delve into the portfolios of...
Source: SeekingAlpha
Date: May, 04 2018 03:18
Blueprint Medicines 2018 Q1 - Results - Earnings Call Slides
The following slide deck was published by Blueprint Medicines in conjunction with their 2018 Q1 earnings Read more ...
Source: SeekingAlpha
Date: May, 02 2018 15:21

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-1369.3069.0770.1868.66200,513
2018-08-1068.3268.8669.7268.26134,087
2018-08-0970.0068.4471.2568.33261,533
2018-08-0871.4669.8271.9069.71722,943
2018-08-0770.6571.5671.9669.91275,261

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-1316,63122,89272.6498Short
2018-08-1028,39143,19465.7290Short
2018-08-0939,53567,22158.8135Short
2018-08-08229,359298,46676.8459Short
2018-08-0732,64872,15745.2458Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on BPMC.


About Blueprint Medicines Corporation (NASDAQ: BPMC)

Logo for Blueprint Medicines Corporation (NASDAQ: BPMC)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $3,549,509,177 - 05/14/2018
  • Issue and Outstanding: 43,837,337 - 04/30/2018

 


Recent Filings from (NASDAQ: BPMC)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 02 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 02 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 27 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 27 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 16 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 21 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: February, 21 2018
Securities offered to employees under employee benefit plans
Filing Type: S-8Filing Source: edgar
Filing Date: February, 21 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 14 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: February, 14 2018

 

 


Daily Technical Chart for (NASDAQ: BPMC)

Daily Technical Chart for (NASDAQ: BPMC)


Stay tuned for daily updates and more on (NASDAQ: BPMC)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: BPMC)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in BPMC is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of BPMC and does not buy, sell, or trade any shares of BPMC. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/